Top 7 Companies in the Chronic Fatigue Syndrome Treatment Market

The chronic fatigue syndrome treatment market was valued at USD 49.18 million in 2023, driven by increased clinical research to find effective treatments across the 8 major markets. The market is expected to grow at a CAGR of 4.2% during the forecast period of 2024-2032, with the values likely to reach USD 71.22 million by 2032.

Chronic Fatigue Syndrome (CFS) is a physical condition that impacts multiple body areas. It leads to extreme tiredness that is not alleviated by rest, cognitive and sleep difficulties, dizziness, pain, and various other symptoms. Individuals with CFS may appear healthy yet are unable to engage in their typical daily tasks. CFS may deteriorate following any physical or mental activity.

Its worldwide occurrence is increasing, with a prevalence of 0.4% to 2.5%; primarily affecting individuals aged 20-40, especially professionally active women. CFS is seen as a prevalent condition in countries like the UK, Australia, and the USA. In the UK alone, it impacts around 250,000 people, with reported rates of up to 0.2%. Fukuda-defined cases in the UK have a prevalence of 0.2%. In the United States, the occurrence of cases defined by Fukuda has been documented to range from 0.2% to 0.4%.

Medical professionals can request laboratory tests to detect conditions with similar symptoms or identify treatable coexisting issues as there are no diagnostic tests for CFS. No one treatment has been proven to be effective for all aspects of CFS, however, there are multiple treatments that can assist in managing symptoms of the condition.

The market for drugs for chronic fatigue syndrome (CFS) is being propelled by rising awareness and identification of the illness, which underscores the substantial unmet medical need resulting from the dearth of FDA-approved CFS medicines. The market is also expanding due to developments in research and development and increasing spending on comprehending the fundamental causes of the illness. The need for efficient treatment alternatives is also being fuelled by the increasing frequency of associated disorders like fibromyalgia.

Pharmaceutical companies are spending more money on research to find possible drug targets and biomarkers that may be used to develop more potent treatments. Furthermore, there is a tendency to use already-approved medications, such as immunomodulatory and antiviral medications, in new ways to treat CFS symptoms.

Top Companies Leading the Chronic Fatigue Syndrome Treatment Market in 2024

1. Pfizer Inc.

Pfizer Inc., an American multinational pharmaceutical and biotechnology company, is based in Manhattan, New York City. Two German entrepreneurs, Charles Pfizer and his cousin Char les F. Erhart, founded the company in 1849 in New York. Some of the most significant medications and vaccines in the world have been created by Pfizer, including a well-liked over-the-counter pain reliever, a well-known medication for the treatment of anxiety and panic disorders, a medication for erectile dysfunction, and a vaccine that may help prevent COVID-19.

2. Cadila Pharmaceuticals Ltd.

Located in Ahmedabad, India, Cadila Pharmaceuticals is a global pharmaceutical firm. The company's operations are concentrated on producing a variety of goods, including pharmaceutical machinery, dietary supplements, completed formulations, biotechnology products, and active pharmaceutical intermediates. Chronic Fatigue Syndrome is reportedly treated with Nucron (generic name: ribavirin ), a medication created by Cadila Pharmaceuticals Ltd.

3. Mylan Pharmaceuticals Inc.

A multinational pharmaceutical corporation, Mylan Inc. (Mylan) develops, licenses, produces, markets, and distributes specialty drugs, active pharmaceutical ingredients (APIs), and generic and branded generic medications. 2020 saw the completion of a global merger between Mylan N.V. and Pfizer Inc. that combined Mylan N.V. and Upjohn (Pfizer's off-patent branded and generic established pharmaceuticals business) to form a new pharmaceutical firm called Viatris Inc. Mylan Laboratories Limited and Mylan Pharmaceuticals Private Limited, became subsidiaries of Viatris Inc. after the global transaction.

4. Mallinckrodt Pharmaceuticals

Mallinckrodt Pharmaceuticals plc is an Irish American company based in the United States that produces imaging agents, generic medications, and specialty pharmaceuticals. 90% of its sales in 2017 came from the US healthcare system. For treating more severe pain than natural opiates, Mallinckrodt provides semi-synthetic restricted narcotics including oxycodone, hydromorphone, and hydrocodone that are made chemically from natural opiates.

5. Eli Lilly and Company

With offices across 18 nations, Eli Lilly and Company is an American pharmaceutical corporation with its headquarters located in Indianapolis, Indiana. Its merchandise is available in about 125 nations. Tirzepatide injection (10 mg or 15 mg) significantly reduced the apnea-hypopnea index ( AHI) compared to placebo, accomplishing the primary endpoints, according to the topline results of the SURMOUNT-OSA phase 3 clinical trials released today by Eli Lilly and Company. One important secondary outcome in both investigations was the percentage change in AHI.

6. Novartis AG

Swiss global pharmaceutical company Novartis AG is situated in Basel, Switzerland. One of the biggest pharmaceutical firms in the world, Novartis has been consistently ranked in the top five globally. In terms of sales, the company was ranked fourth in 2022. Sertraline from Novartis AG is recommended for treating several conditions, including, major depressive episodes, major depressive episode recurrence prevention in adults and pediatric patients aged 6-17 years, panic disorder, with or without agoraphobia, post-traumatic stress disorder (PTSD) and social anxiety.

7. Sun Pharmaceutical Industries Ltd

With its global headquarters located in Mumbai, Sun Pharmaceutical Industries Limited is an Indian multinational pharmaceutical firm that produces and distributes active pharmaceutical ingredients and pharmaceutical formulations to over 100 countries worldwide. Duloxetine is one of the drugs offered by Sun Pharmaceutical Industries Ltd.; while it isn't licensed for use in treating chronic fatigue syndrome, it can help treat symptoms like depression and chronic pain. Although they don't have a specific medication for CFS, their goods provide symptom alleviation possibilities. A healthcare professional should always be the one to direct treatment.